Eupraxia Pharmaceuticals is making significant progress with its EP-104GI treatment and has now commenced the second cohort of its early-stage trial in eosinophilic esophagitis.
Dose Escalation Approved by Safety Review Committee
Following the favorable outcomes observed in the trial's first cohort, Eupraxia's safety review committee has granted approval for a dose escalation in the second cohort. Notably, EP-104GI has been proven to be well tolerated, with no drug-related adverse events reported.
Protocol Amendment Submitted for Enhanced Assessments
To further enhance the trial's efficacy assessment and better understand its pharmacokinetics, Eupraxia has submitted an amendment to the protocol. This amendment includes additional assessments to be conducted at the six-month mark across all cohorts.
Trial Details and Enrollment
The Phase 1b/2a trial adopts a dose-ascending approach and consists of three patients per cohort. With a maximum of five cohorts, Eupraxia aims to have a total enrollment of up to 15 patients from esteemed medical centers in Canada, the Netherlands, and Australia.
Building on Success in Osteoarthritis Treatment
The initiation of the second cohort follows the recent completion of a Phase 2b clinical trial for Eupraxia's lead product candidate, EP-104IAR. This innovative treatment targets pain relief in individuals with osteoarthritis of the knee.
Our Latest News
Technology Stocks Witness Decline Amid AI Correction
The technology stocks' decline amidst the ongoing AI correction highlights the market's need for realistic assessment of valuations and expectations. Investors...
The Debate on Proprietary vs. Open Source Language Models
A key debate in the world of artificial intelligence revolves around whether large language models should be proprietary or open source. The AI Alliance, formed...
Wheat Futures Decline on Rising Global Production Forecast
Wheat futures decline due to an increase in global production forecast, despite projected consumption exceeding production levels.